Search - tctmd.com

Displaying 121 - 140 of 1213

Sort: Relevancy | Date

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Shelley Wood

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

Shelley Wood

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News VIVA 2024

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

L.A. McKeown

November 14, 2024

News Daily News

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

Todd Neale

November 13, 2024

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

Todd Neale

November 13, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

L.A. McKeown

October 25, 2024

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Daily News

AHA Statement Outlines Cardiac Contributions to Brain Health

L.A. McKeown

October 11, 2024

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

News Daily News

Low CV Risk With ‘Living’ Cancer Therapies, Meta-analysis Shows

L.A. McKeown

October 09, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Todd Neale

October 01, 2024

Advertisement

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

October 2024 Dispatch for the CV Team

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

AHA Statement Outlines Cardiac Contributions to Brain Health

Will Semaglutide Change Cardiac Surgery? It Already Has

Low CV Risk With ‘Living’ Cancer Therapies, Meta-analysis Shows

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content